| Name | Title | Contact Details |
|---|
Biotronik is a leader in cardio- and endovascular medical technology (pacemakers, implantable defibrillators, stents and remote patient management). We put our heart in it. From its headquarters in Berlin, Germany, BIOTRONIK operates in more than 100 countries around the world, offering products and services essential to the lives of people living with cardiac conditions. BIOTRONIK employs highly committed employees who undertake tenacious research and development and meticulous manufacturing to meet this huge responsibility. BIOTRONIK´s products are designed, produced and sold by people who put their hearts into their work. Quality in every detail. From the very start, BIOTRONIK dedicated itself to driving progress and innovation and delivering exceptional quality. We have earned the trust of medical professionals and patients by combining the renowned art of German engineering with technical excellence and uncompromising quality standards. This dedication is evident in everything we do. High achievers are welcome. Medical engineering is an industry of the future. In a field marked by rapid developments and short innovation cycles, the best guarantees for sustainable success are committed, creative, team-oriented specialists, and outstanding leadership. If you are passionate about computer science, engineering or the natural sciences and enjoy developing new ideas, you´ve found the right place.
Quantum Medical Imaging is a Ronkonkoma, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Reconnect Mental Health Services is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Truly Instrument Limited is a Alhambra, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.